These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17059170)

  • 1. Lipophilicity relationships in inhibitors of CYP2C9 and CYP2C19 enzymes.
    Lewis DF; Lake BG; Ito Y; Dickins M
    J Enzyme Inhib Med Chem; 2006 Aug; 21(4):385-9. PubMed ID: 17059170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors.
    Suzuki H; Kneller MB; Rock DA; Jones JP; Trager WF; Rettie AE
    Arch Biochem Biophys; 2004 Sep; 429(1):1-15. PubMed ID: 15288804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative structure-activity relationships (QSARs) for inhibitors and substrates of CYP2B enzymes: importance of compound lipophilicity in explanation of potency differences.
    Lewis DF; Ito Y; Lake BG
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):679-84. PubMed ID: 20100069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfaphenazole derivatives as tools for comparing cytochrome P450 2C5 and human cytochromes P450 2Cs: identification of a new high affinity substrate common to those enzymes.
    Marques-Soares C; Dijols S; Macherey AC; Wester MR; Johnson EF; Dansette PM; Mansuy D
    Biochemistry; 2003 Jun; 42(21):6363-9. PubMed ID: 12767217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative structure-activity relationships (QSARs) in inhibitors of various cytochromes P450: the importance of compound lipophilicity.
    Lewis DF; Lake BG; Dickins M
    J Enzyme Inhib Med Chem; 2007 Feb; 22(1):1-6. PubMed ID: 17373540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19.
    Reynald RL; Sansen S; Stout CD; Johnson EF
    J Biol Chem; 2012 Dec; 287(53):44581-91. PubMed ID: 23118231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
    Yamazaki H; Shimada T
    Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.
    Lewis DF
    Arch Biochem Biophys; 2003 Jan; 409(1):32-44. PubMed ID: 12464242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design.
    Wang JF; Wei DQ; Li L; Zheng SY; Li YX; Chou KC
    Biochem Biophys Res Commun; 2007 Apr; 355(2):513-9. PubMed ID: 17307149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily.
    Usmani KA; Karoly ED; Hodgson E; Rose RL
    Drug Metab Dispos; 2004 Mar; 32(3):333-9. PubMed ID: 14977868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human cytochrome p450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1'-hydroxymethyleugenol.
    Jeurissen SM; Bogaards JJ; Boersma MG; ter Horst JP; Awad HM; Fiamegos YC; van Beek TA; Alink GM; Sudhölter EJ; Cnubben NH; Rietjens IM
    Chem Res Toxicol; 2006 Jan; 19(1):111-6. PubMed ID: 16411663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
    Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
    Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of enzyme selectivity in the human CYP2C subfamily: homology modelling of CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 crystallographic template.
    Lewis DF; Dickins M; Lake BG; Goldfarb PS
    Drug Metabol Drug Interact; 2003; 19(4):257-85. PubMed ID: 14768974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA.
    Ridderström M; Zamora I; Fjellström O; Andersson TB
    J Med Chem; 2001 Nov; 44(24):4072-81. PubMed ID: 11708911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of binding modes of (S)-mephenytoin to wild types and mutants of cytochrome P450 2C19 and 2C9 using homology modeling and computational docking.
    Oda A; Yamaotsu N; Hirono S
    Pharm Res; 2004 Dec; 21(12):2270-8. PubMed ID: 15648259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.
    Yao M; Zhu M; Sinz MW; Zhang H; Humphreys WG; Rodrigues AD; Dai R
    J Pharm Biomed Anal; 2007 May; 44(1):211-23. PubMed ID: 17418993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
    Zand N; Tajik N; Moghaddam AS; Milanian I
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.